Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 5/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.48 |
| ▸ | SYK | P43405 | 5/20 | 0.48 |
| ▸ | PRKCI | P41743 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 3/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
| ▸ | IGF1R | P08069 | 1/20 | 0.40 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.40 |
| ▸ | AXL | P30530 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 2/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14320439 | 0.93 | JAK2 (0.50) | JAK2PDGFRBPDGFRASYKPRKCI | |
| SCHEMBL14320719 | 0.90 | SYK (0.51) | JAK2SYKBRD4CREBBPMTOR | |
| SCHEMBL14320792 | 0.85 | JAK2 (0.65) | JAK2PDGFRBPDGFRASYKCDK9 | |
| SCHEMBL27932672 | 0.84 | JAK2 (0.49) | JAK2SYKPDE4BPDE4D | |
| SCHEMBL14321220 | 0.84 | JAK2 (0.62) | JAK2SYK | |
| SCHEMBL14320433 | 0.84 | PDGFRB (0.48) | PDGFRBPDGFRASYKPRKCIPDE4B | |
| SCHEMBL15650152 | 0.82 | TYK2 (0.54) | JAK2PDGFRBPDGFRASYKPRKCI | |
| SCHEMBL14320662 | 0.81 | JAK2 (0.51) | JAK2SYK | |
| SCHEMBL15652144 | 0.81 | ABCG2 (0.47) | PDGFRBPDGFRAPRKCIBRD4PDE4D | |
| SCHEMBL14321127 | 0.80 | JAK2 (0.61) | JAK2PDGFRBPDGFRASYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9802937-B2 | Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-10-31 | — | — | US | claimed |
| CN-103492389-A | Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors | ORIGENIS GMBH | 2014-01-01 | — | — | CN | claimed |
| US-20120329780-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | claimed |
| US-9802937-B2 | Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-10-31 | — | — | US | disclosed |
| EP-2699579-B1 | PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-10-07 | — | — | EP | disclosed |
| EP-2699579-A1 | PYRAZOLO [4, 3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS | Origenis GmbH (DE) | 2014-02-26 | — | — | EP | disclosed |
| CN-103492389-A | Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors | ORIGENIS GMBH | 2014-01-01 | — | — | CN | disclosed |
| US-20120329780-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| WO-2012143144-A1 | PYRAZOLO [4, 3-D] PYRIMIDINES USEFUL AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329780-A1 | Novel kinase inhibitors | LRRK2, MYLK2, MYLK | JAK2 60/4885PDGFRB 484/4885PDGFRA 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.